{
    "clinical_study": {
        "@rank": "80553", 
        "arm_group": {
            "arm_group_label": "A single-arm study", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "Accumulating evidence suggests a role of G protein-coupled inwardly-rectifying potassium\n      (GIRK) channel in the pathology of excitement of nerve, and the medicine with the action\n      (like the Tipepidine Hibenzate) is expected as a new curative medicine of adolescent\n      depression.\n\n      The purpose of this research is to confirm the effect by carrying out the additional dosage\n      of the Tipepidine Hibenzate to the adolescent patients with depression.\n\n      If suggestion is obtained by this research about the effect on adolescent patients with\n      depression of Tipepidine Hibenzate, it can contribute to development of the medical\n      treatment of adolescent patients with depression."
        }, 
        "brief_title": "An Open Study of Tipepidine Hibenzate in Adolescent Patients With Depression", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "condition": [
            "Depression", 
            "Adolescent"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Depression", 
                "Depressive Disorder"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "[Inclusion Criteria]\n\n          1. Depressive Episode for ICD-10 criteria.\n\n          2. Patients are treated with antidepressants (SSRI ; Fluvoxamine, Paroxetine,\n             Sertraline, Escitalopram, SNRI ; Milnacipran, Duloxetine, NaSSa; Mirtazapine), mood\n             stabilizers (Lithium, Sodium Valproate, Carbamazepine, Lamotrigine), atypical\n             antipsychotics (Risperidone, Olanzapine, Quetiapine, Perospirone, Aripiprazole,\n             Blonanserin, Paliperidone) or not treated.\n\n          3. Patients are stable for 4-weeks for medication.\n\n        [Exclusion Criteria]\n\n          1. Patients with a previous hypersensitivity to Tipepidine Hibenzate.\n\n          2. Patients treated with typical antipsychotics and antidepressants except inclusion\n             criteria 2.  and mood stabilizers except inclusion criteria 2.\n\n          3. Pregnant or breast-feeding women"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "18 Years", 
            "minimum_age": "10 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01835847", 
            "org_study_id": "G24062"
        }, 
        "intervention": {
            "arm_group_label": "A single-arm study", 
            "intervention_name": "Tipepidine Hibenzate", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 22, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Chiba", 
                    "country": "Japan", 
                    "state": "Chuo-ku", 
                    "zip": "260-8670"
                }, 
                "name": "Department of Psychiatry, Chiba University School of Medicine"
            }
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "Tipepidine for Adolescent Depression", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Japan: Institutional Review Board"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The CDRS-R is a brief rating scale based on a semi-structured interview with the child (or an adult informant who knows the child well). Designed for 6- to 12-year-olds, and successfully used with adolescents, it can be administered in just 15 to 20 minutes and easily scored in a few minutes more. The interviewer rates 17 symptom areas (including those that serve as DSM-IV criteria for a diagnosis of depression):", 
            "measure": "Children's Depression Rating Scale, Revised (CDRS-R)", 
            "safety_issue": "Yes", 
            "time_frame": "Changes from baseline in CDRS-R at 4-weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01835847"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Chiba University", 
            "investigator_full_name": "Tsuyoshi Sasaki", 
            "investigator_title": "Assistant Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "results_reference": {
            "PMID": "24833905", 
            "citation": "Sasaki T, Hashimoto K, Tachibana M, Kurata T, Kimura H, Komatsu H, Ishikawa M, Hasegawa T, Shiina A, Hashimoto T, Kanahara N, Shiraishi T, Iyo M. Tipepidine in adolescent patients with depression: a 4 week, open-label, preliminary study. Neuropsychiatr Dis Treat. 2014 May 5;10:719-22. doi: 10.2147/NDT.S63075. eCollection 2014. PubMed"
        }, 
        "secondary_outcome": {
            "description": "DSRS-C is easy to use and has a predictive value comparable with that of a psychiatric global rating of depressed appearance and history of depression obtained at interview. There was confirmation that the DSRS-C can tap an internal dimension of depression and that children are able to evaluate their feeling states.", 
            "measure": "Depression Self-Rating Scale for Children (DSRS-C) Japenese Version", 
            "safety_issue": "Yes", 
            "time_frame": "Changes from baseline in DSRS-C at 4-weeks"
        }, 
        "source": "Chiba University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chiba University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}